Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.
Boston – September 15, 2026 -- EMD Serono, Inc., the healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has acquired two preclinical fertility drug programs from PostEra, a biotech firm built on artificial intelligence-driven small molecule discovery.
Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from Boston-based biotech PostEra, the companies announced.
Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.
Berlin – September 15, 2026 -- The European Commission is redrawing public procurement rules to treat supply security as a strategic asset, pressuring Germany to overhaul how statutory health insurers award pharmaceutical rebate contracts.
Berlin – – September 15, 2026 -- The European Commission today unveiled the EU Public Procurement Act (PPA), a comprehensive proposal to modernize European procurement law, drawing an immediate response from Germany's pharmaceutical industry association BPI.
Galway, Ireland – – September 13, 2026 -- Neurent Medical has secured a €25 million growth debt financing facility from Claret Capital Partners to accelerate commercial expansion of its NEUROMARK® System for chronic rhinitis treatment.
San Rafael, Calif. – September 13, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO (vosoritide) met its primary endpoint in children with hypochondroplasia, with results published in NEJM Evidence and presented at the European Society for Paediatric Endocrinology 2026 Annual Meeting.
New York – September 13, 2026 -- Michael J. Fox, founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF), has been named a laureate of the 2026 Lasker~Bloomberg Public Service Award, one of America's most prestigious biomedical research prizes. The Lasker Foundation cited Fox for "dispelling the stigma of the disease and spearheading a revolution in the world of Parkinson's research." More than 100 past Lasker Laureates have gone on to win the Nobel Prize.
San Jose, Calif. – September 13, 2026 -- Anixa Biosciences, Inc. (NASDAQ: ANIX) confirmed that Bloomberg TV will air an interview with Chairman and CEO Dr. Amit Kumar and breast cancer vaccine trial patient Sherie Steinberg this Saturday, September 12, at 7:00 PM ET, reaching an estimated 73 million U.S. homes.
